Commercialization of the BACTEC FXI blood-culture system to replace an aged installed base in microbiology labs.
Launch of the FACSDiscover A7 spectral flow cytometer on September 15, 2026 into a recovering biotech and academic funding environment.
Localization of the flow cytometry portfolio and manufacturing in China, with full portfolio availability in Q4 2026.
Instrument outfitting for U.S. pharma reshoring and expansion projects over the next three to five years.
Raised FY2026 organic revenue growth guidance to 7%-9%, reflecting broader end-market recovery and acquired-business momentum.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Waters Corporation and 4,900+ companies.